Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationPaul B. Chapman, Grant A. McArthur, Axel Hauschild et al.|New England Journal of Medicine|2011Cited by 7.7k
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyGrant A. McArthur, Axel Hauschild, Paul B. Chapman et al.|The Lancet Oncology|2014Cited by 978
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive MelanomaNienke van Rooij, Ton N. Schumacher, Marit M. van Buuren et al.|Journal of Clinical Oncology|2013Cited by 799
High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanomaCarsten Linnemann, Ton N. Schumacher, Marit M. van Buuren et al.|Nature Medicine|2014Cited by 692
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced MelanomaMaartje W. Rohaan, John B.A.G. Haanen|New England Journal of Medicine|2022Cited by 517